AlphAIAlphAI — Financial news for AI agents
marketscreener.comSEP 241 min read$ARCT

Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8

Citigroup upgraded Arcturus Therapeutics to Buy from Neutral and raised its price target to $20 from $8. The stock has seen a 5-day change of $13.30, a 1st Jan change of -7.51%, and a 1-year change of +116.97%. The upgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

Original reporting
marketscreener.com
Published Sep 24, 2026, 10:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 11:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ARCT
Bullish
medium confidence
Mentioned
$ARCT
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ARCTBullishMed
01

Why it matters

Analyst upgrade may attract new buying interest and support price.

02

Market read

The upgrade is a fresh catalyst for ARCT, likely prompting short-term buying.

03

What to watch

Potential regulatory or clinical trial risks not addressed in the upgrade.

Relevance 7/10Novelty 7/10Timing: today

Background

Arcturus Therapeutics is a biotech firm developing mRNA therapeutics.

Company-level read

Ticker impact

$ARCTBullishMedium confidence
Context

Citi upgraded Arcturus Therapeutics to Buy and raised its price target to $20 from $8.

Expected impact

Potential price increase toward the new $20 target.

Evidence & confidence

Upgrade and higher target indicate improved valuation expectations.

Market effects

Sector

May lift sentiment for biotech and RNA therapeutics sector.

Regional

Limited to US biotech investors.

Global

Minor global impact.

Counterpoint

What could challenge this read

Upgrade could be premature if upcoming trial data disappoints.

Key entities

  • Analyst
    Citigroup

    Provided the upgrade and new price target.

Read at source← All news

Related articles

SEP 1
$ARCTMed

Why is Arcturus Therapeutics stock surging today?

Arcturus Therapeutics (ARCT) shares rose 10.7% after announcing participation in five investor conferences in September 2026, signaling confidence in its pipeline. The company has a cash position of $191M and a strategic collaboration with Thermo Fisher. Analysts maintain a Buy rating, and the stock hit a session high of $16.45, despite broader market declines.

investing.com2 min
AUG 22
$ARCTMed

ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’

Arcturus Therapeutics (ARCT) shares surged over 60% this week, driven by sector-wide enthusiasm for mRNA technology and company-specific progress. The rally began after positive late-stage results from Merck and Moderna's mRNA cancer vaccine. ARCT's pipeline focuses on rare diseases, with key trials expected to report data in 2026. The company recently regained full rights to its COVID vaccine, KOSTAIVE, and has a solid balance sheet. Despite recent challenges, retail sentiment has turned extrem

newsable.asianetnews.com2 min
AUG 14
$ARCTMedAI 8/10

Arcturus (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) reported Q2 2026 revenue of $3M ($5M for six months) versus $28.3M and $57.7M a year earlier, citing lower recognition tied to the CSL Seqirus collaboration termination process. Net loss was $23.8M ($0.84/share). Cash was $191.5M, with a runway through 2028. Company regained global rights to KOSTAIVE and received a $12M one-time payment. Phase II ARCT-032 enrollment continues, with a Phase III decision expected in Q4 2026.

fool.com7 min
AUG 7
$ARCTMed

Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership

Arcturus Therapeutics (Nasdaq: ARCT) terminated its sa-mRNA vaccine partnership with CSL Seqirus via a settlement. Arcturus regained global rights to KOSTAIVE (ARCT-154) and other vaccine programs. CSL Seqirus will pay $12m cash, and Arcturus is released from about $16m in R&D credits, totaling about $28m. The deal unwinds a pact valued around $4.3b.

allsci.com4 min